Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.35 |
| ▸ | NQO1 | P15559 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17841422 | 0.81 | CYP1A2 (0.37) | CYP1A1CYP1A2CYP1B1KDM4ECYP2C19 | |
| SCHEMBL24297786 | 0.79 | CYP1A2 (0.35) | MEN1KMT2AL3MBTL1CYP1A1CYP1A2 | |
| SCHEMBL27461868 | 0.78 | CYP1A2 (0.36) | MEN1KMT2AATMRCE1L3MBTL1 | |
| SCHEMBL3406206 | 0.77 | NPSR1 (0.46) | KDM4EMCL1 | |
| SCHEMBL22432740 | 0.77 | ALOX5 (0.46) | MEN1KMT2ACYP1A1CYP1A2CYP1B1 | |
| SCHEMBL2268151 | 0.75 | MAOA (0.44) | MEN1KMT2AATML3MBTL1CYP1A1 | |
| SCHEMBL433952 | 0.74 | CYP1A2 (0.46) | CYP1A1CYP1A2CYP1B1KDM4ECYP3A4 | |
| SCHEMBL24297504 | 0.74 | CYP1A1 (0.38) | CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL17841487 | 0.74 | MCL1 (0.43) | CYP1A1CYP1A2CYP1B1KDM4EMCL1 | |
| SCHEMBL16047773 | 0.73 | MCL1 (0.41) | MAOBMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254647-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-22 | — | — | US | disclosed |
| EP-3421458-B1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-11 | — | — | EP | disclosed |
| US-20200317629-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-08 | — | — | US | disclosed |
| US-10730847-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-04 | — | — | US | disclosed |
| US-20190152937-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-23 | — | — | US | disclosed |
| EP-3421458-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | Janssen Pharmaceutica NV (BE) | 2019-01-02 | — | — | EP | disclosed |
| US-10155737-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-18 | — | — | US | disclosed |
| EP-2970157-B1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-25 | — | — | EP | disclosed |
| US-20170088531-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-30 | — | — | US | disclosed |
| US-9562053-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-07 | — | — | US | disclosed |
| US-20140275172-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| EP-1027043-B1 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-11-10 | — | — | EP | disclosed |
| CN-1152679-C | Melatonergic agents of benzodioxoles, benzofurans, dihydrobenzofurans and benzodioxanes | ����˹�ж�-����˹˹������˾ | 2004-06-09 | — | — | CN | disclosed |
| EP-1027043-A4 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2002-02-20 | — | — | EP | disclosed |
| EP-1027043-A1 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | Bristol-Myers Squibb Company (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6060506-A | FOR TREATMENT OF SLEEP DISORDERS, CIRCADIAN RHYTHM DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
| CN-1239886-A | Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agent | BRISTOL MYERS SQUIBB CO (US) | 1999-12-29 | — | — | CN | disclosed |
| US-5981571-A | USEFUL AS MELATONERGIC AGENTS IN THE TREATMENT OF SLEEP DISORDERS, SEASONAL DEPRESSION, SHIFTS IN CIRCADIAN CYCLES, MELANCHOLIA, STRESS, APPETITE REGULATION, BENIGN PROSTATIC HYPERPLASIA AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-11-09 | — | — | US | disclosed |
| US-5856529-A | ADJUSTMENT OF NERVOUS SYSTEM, ENDOCRINE FUNCTION; REPRODUCTION, BODY WEIGHT AND METABOLISM | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-01-05 | — | — | US | disclosed |
| WO-1998025606-A1 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155737-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | MEN1 4390/4885KMT2A 2759/4885ATM 4372/4885 |
| US-20200317629-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | MEN1 4390/4885KMT2A 2759/4885ATM 4372/4885 |
| US-20190152937-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | MEN1 4390/4885KMT2A 2759/4885ATM 4372/4885 |
| US-20140275172-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | MEN1 4390/4885KMT2A 2759/4885ATM 4372/4885 |
| US-20170088531-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | MEN1 4390/4885KMT2A 2759/4885ATM 4372/4885 |
| US-11254647-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | MEN1 4390/4885KMT2A 2759/4885ATM 4372/4885 |
| US-10730847-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | MEN1 4390/4885KMT2A 2759/4885ATM 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.